Fluvoxamine treatment of major depression associated with multiple sclerosis

Francesco Benedetti, Euridice Campori, Cristina Colombo, Enrico Smeraldi

Research output: Contribution to journalArticlepeer-review

Abstract

Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon β-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.

Original languageEnglish
Pages (from-to)364-366
Number of pages3
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 2004

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Fingerprint

Dive into the research topics of 'Fluvoxamine treatment of major depression associated with multiple sclerosis'. Together they form a unique fingerprint.

Cite this